This is an aggregated industry headline. Read the full story at BioPharma Dive →
J&J looks to widen Imaavy's use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
By BioPharma Dive
· Jun 11, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The Considered+AI is an AI-native agency that's been rooted in generative AI tools since its start in 2021.…
The WeekFierceBiotech ↗
Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella's i…
The WeekBriefing
Freenome’s blood-based colorectal cancer test won FDA approval, and Abbott will exclusively market it in the U…